HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
MBRX
Moleculin Biotech, Inc.
There isn't enough reported data to score MBRX yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
MBRX Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
MBRX's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
MBRX PE Valuation
MBRX has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
MBRX Forward outlook
There aren't enough analyst estimates for MBRX to show an outlook.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
MBRX has the stronger earnings trend. Trailing diluted EPS is down 257% for HIMS versus MBRX down 120%.
MBRX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2025 | -$1,203.31 | +$4,680.63 |
| Q2 2025 | -$2,288.31 | +$3,595.63 |
| Q1 2025 | -$2,893.31 | +$3,640.63 |
| Q4 2024 | -$3,558.31 | +$4,065.63 |
| Q3 2024 | -$5,883.94 | +$916.14 |
| Q2 2024 | -$5,883.94 | +$1,741.14 |
| Q1 2024 | -$6,533.94 | +$1,391.14 |
| Q4 2023 | -$7,623.94 | +$1.14 |
MBRX is still losing money, but far less than before: $1,203.31 per share over the past year, against $16,200.00 at its worst in late 2019.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over MBRX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
MBRX Quarterly Revenue
MBRX's revenue is shrinking: $0 last quarter.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over MBRX on cash generation, producing positive trailing cash flow while its opponent burns cash.
MBRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$6.7M | -$1.1M |
| Q1 2026 | -$6.1M | -$1.5M |
| Q4 2025 | -$5.4M | -$283K |
| Q3 2025 | -$7.2M | -$1.1M |
| Q1 2025 | -$4.6M | +$2.2M |
| Q4 2024 | -$5.1M | +$405K |
| Q3 2024 | -$6.1M | +$1.5M |
| Q1 2024 | -$6.7M | -$700K |
MBRX has burned cash in almost every quarter: −$25M over the past year, against −$21M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over MBRX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
MBRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +38% | +77.8K shares |
| 1 year | +1420% | +265K shares |
| 3 years | +7310% | +280K shares |
| 5 years | +9667% | +281K shares |
| Available history | +28022% | +283K shares |
MBRX has 284,036 diluted shares, up 1420% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
MBRX Net Leverage
MBRX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
MBRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 31.7 | Neutral |
| Stochastic | 25.0 | Neutral |
MBRX's weekly RSI is 32 (neutral) and its Stochastic is 25 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
MBRX PE vs Healthcare Sector
MBRX has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
MBRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $8.42 | 4.3% below |
| 20 week MA | $17.4 | 54% below |
| 50 week MA | $45.4 | 82% below |
| 100 week MA | $237.5 | 97% below |
| 200 week MA | $2,059.1 | 100% below |
MBRX is in a downtrend: it's below all five of its weekly moving averages, and 100% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over MBRX on returns for 2026, with the stronger performance.
MBRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $43,950.2 | $39,155.0 | -11% |
| 2021 | $39,155.0 | $15,225.0 | -61% |
| 2022 | $15,225.0 | $9,075.0 | -40% |
| 2023 | $9,075.0 | $6,440.0 | -29% |
| 2024 | $6,440.0 | $825.0 | -87% |
| 2025 | $825.0 | $76.6 | -91% |
| 2026 YTD | $76.6 | $8.06 | -89% |
MBRX has finished every year since 2020 lower, and it's down 89% so far in 2026.